Business Context and Reporting Period
This Form 8-K is a current report filed by Genesis Biopharma, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) on February 23, 2011, covering events occurring on February 22, 2011. The company is a Nevada corporation headquartered in Manhattan Beach, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Dr. L. Stephen Coles to the Company's Board of Directors effective February 22, 2011.
- Compensation: Dr. Coles will receive a monthly payment of $3,000 for his services.
- Background: Dr. Coles is a lecturer at UCLA and has held senior roles at The Kronos Group, Image Date Corporation, and Rcommunity.com, Inc.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the director appointment and associated compensatory arrangement.
Investor Verification Checklist
- Verify the correct issuer name is Genesis Biopharma, Inc., as the input metadata referenced IOVANCE BIOTHERAPEUTICS, INC.
- Confirm the effective date of Dr. Coles' board appointment (February 22, 2011).
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.